window.pageData = {"stock":{"_id":3000000022691,"name":"华安医药生物股票型发起式证券投资基金","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"022691","tickerId":22691,"shortName":"华安医药生物股票发起式C","currency":"CNY","exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"inceptionDate":"2024-12-26T16:00:00.000Z","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"followedNum":1,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50040000","tickerId":50040000,"name":"华安基金管理有限公司"},"managers":[{"name":"桑翔宇","stockType":"fund_manager","stockCode":"db20909245","exchange":"fm","tickerId":192425235320}],"hotMetrics":{"fss":{"stockId":3000000022691,"type":"fss","last_data_date":"2025-06-29T16:00:00.000Z","f_ins_h_s_r":0.0983,"f_ind_h_s_r":0.9017000000000001,"f_h_a":13296},"fpr":{"stockId":3000000022691,"type":"fpr","f_p_r_fys_ssc":5565,"f_p_r_fys_ssrp":0.9539899352983465,"f_p_r_m1_ssc":5828,"f_p_r_m1_ssrp":0.9900463360219667,"f_cagr_p_r_fs_ssc":5894,"f_cagr_p_r_fs_ssrp":0.17257763448158833,"f_p_r_m3_ssc":5700,"f_p_r_m3_ssrp":0.9613967362695209,"f_p_r_m6_ssc":5388,"f_p_r_m6_ssrp":0.9951735659922034,"f_p_r_y1_ssc":4646,"f_p_r_y1_ssrp":0.9231431646932186},"fp":{"stockId":3000000022691,"type":"fp","f_p_r_d1":0.0005862155598359564,"f_p_r_fys":-0.1134531140879943,"f_cagr_p_r_fs":0.27012525118702047,"f_p_r_m1":-0.133209186840472,"last_data_date":"2026-05-19T16:00:00.000Z","f_p_r_m3":-0.13105164903546995,"f_p_r_m6":-0.21515287769784153,"f_p_r_y1":-0.035835117033763964},"ff":{"stockId":3000000022691,"type":"ff","f_fr_d":"2025-09-18T16:00:00.000Z","f_m_fr":0.012,"f_c_fr":0.002,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000022691,"type":"f_nlacan","f_nv_d":"2026-05-19T16:00:00.000Z","f_nv":1.3964,"f_nv_cr":0.009251228678808898},"f_as":{"stockId":3000000022691,"type":"f_as","f_tas":252934037.79,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":1000000000001530,"holdings":3802000,"marketCap":76001934,"netValueRatio":0.0712,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":603259,"holdings":713573,"marketCap":70001511,"netValueRatio":0.0656,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":1000000000001801,"holdings":889500,"marketCap":66679103,"netValueRatio":0.0625,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":600276,"holdings":1205481,"marketCap":66566660,"netValueRatio":0.0624,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":300765,"holdings":1983300,"marketCap":62989608,"netValueRatio":0.059,"quarterlyChange":-0.11948988078735767,"stock":{"stockCode":"300765","exchange":"sz","stockType":"company","tickerId":300765,"name":"新诺威"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":688331,"holdings":483221,"marketCap":62224368,"netValueRatio":0.0583,"quarterlyChange":0.6553541586322154,"stock":{"name":"荣昌生物","exchange":"sh","stockType":"company","stockCode":"688331","tickerId":688331}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":1000000000009926,"holdings":537000,"marketCap":61733568,"netValueRatio":0.0578,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":1000000000006990,"holdings":142900,"marketCap":58039835,"netValueRatio":0.0544,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":688266,"holdings":526867,"marketCap":52054459,"netValueRatio":0.0488,"quarterlyChange":0.06580366774541457,"stock":{"stockCode":"688266","tickerId":688266,"exchange":"sh","stockType":"company","name":"泽璟制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockId":1000000000002268,"holdings":973500,"marketCap":50025916,"netValueRatio":0.0469,"quarterlyChange":-0.04197530864197552,"stock":{"stockCode":"02268","exchange":"hk","stockType":"company","tickerId":2268,"name":"药明合联"}}],"bondHoldings":[{"_id":"69e8fbba1398d79843003dae","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000022690,"stockCode":"019773","stockName":"25国债08","holdings":18000,"marketCap":1823894,"netValueRatio":0.0017,"lastUpdated":"2026-04-22T16:47:54.606Z"}]},"list":[{"_id":"69e8ec751398d79843fe9e5a","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000022690,"sao":"我们依然看好国内创新药产业发展趋势，所以核心仓位还是坚持在创新药板块，特别是港股创新药；CXO板块今年体现出持续复苏迹象，因此我们看好全年cxo的pe和eps修复，在一季度继续增加了cxo板块的配置。","lastUpdated":"2026-04-22T15:42:45.833Z","fund":{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"db20909245","stockType":"fund_manager","exchange":"fm","tickerId":192425235320,"name":"桑翔宇"}]},"announcement":{"linkText":"华安医药生物股票型发起式证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1475082","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3d17fea5b3eb0541c32","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000022690,"sao":"四季度医药板块较弱，我们依然坚持在医药景气度最好的创新药赛道上，保持着70%以上的创新药仓位，且以港股创新药为主，其次配置了部分CXO和器械板块，等待产业景气恢复。","lastUpdated":"2026-03-09T14:06:09.780Z","fund":{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"db20909245","stockType":"fund_manager","exchange":"fm","tickerId":192425235320,"name":"桑翔宇"}]},"announcement":{"linkText":"华安医药生物股票型发起式证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1459700","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3d17fea5b3eb0541c31","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000022690,"sao":"创新药经历过今年二季度的出色表现，三季度末表现平淡，目前看创新药的产业趋势依然可持续，但是在市场预期上需要重新审视和纠正。目前依然维持创新药主线地位，CXO和器械次线地位的配置策略。　　（1）创新药在今年3-6月份属于炒数据阶段，6-9月份属于炒BD阶段。中国凭借工程师红利确实在部分领域上完成弯道超车，在部分领域，比如ADC、PD1双抗上我们表现出非常好的领先身位，但需要注意我们并不是在所有领域全面领先。所以创新药的BD大家预期较高，最后低于预期可能性存在。我的理解是在接下来的时间到一季度末，任何创新药的回调都是为明年跌出空间。海外来看未来美国虽然推出行政命令限制中国企业BD的可能性很小，但是行政命令的另一方面是对临床数据要求提高；MNC购买优质性价比资产意愿依然存在，但是只有特别好的资产才会以大总包金额BD出去，所以我们可能需要适当降低BD的总包预期和数量；创新药本身是一个竞争性产品，同适应症的治疗产品，随着玩家增多，一家数据特别好会对其他公司造成一定压力。综合以上情况看，我们觉得创新药的预期需要合理修正，产业趋势依然存在并且可持续，但是未来的赢家和兑现一定是少数优质企业，β的时代可能会过渡到α的时代。　　（2）CXO和医疗器械在未来投资中值得重视，两个行业的海外需求目前都仍在景气区间，国内明年需求看不清楚，需要进一步观察；虽然生物安全法通过概率在提高，但是最后会变成长期压制估值的东西，核心还是看基本面到底怎么样，基本面如果持续向上，海外的扰动就不足为惧。　　整体看，医药已经从今年创新药全面给到估值溢价，过度到精选个股状态，之后我们需要深入挖掘研究，希望给投资人选择更好的标的，获取更好的收益。","lastUpdated":"2026-03-09T14:06:09.777Z","fund":{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"db20909245","stockType":"fund_manager","exchange":"fm","tickerId":192425235320,"name":"桑翔宇"}]},"announcement":{"linkText":"华安医药生物股票型发起式证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1375704","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3d17fea5b3eb0541c30","date":"2025-06-29T16:00:00.000Z","stockId":3000000022690,"sao":"在一季度的行情展望中，我们分析了医药的投资思路，简单来讲三句话：1、创新药是全年的主线；2、AI医疗是全年的主题；3、Q3-Q4困境反转类的公司会有阶段性机会；二季度医药领域继续演绎创新药的逻辑，并且超额收益非常明显；站在当前时间点，我们想从产业和未来投资节奏上粗略展开下阶段的投资策略和运作分析：　　创新药是年维度的行情机会，不会因为阶段性的调整结束；目前我觉得市场依然对于创新药产业崛起的量级是有所低估的，原因是因为：1、中国已经成为全球大分子药物研发中心和制造中心：中国依靠工程师红利，实现了制药领域的DeepSeek时刻；2、未来基石用药绝大部分来自中国：过去的基石用药是PD1+化疗等，未来化疗升级到ADC、PD1升级到PD1双抗产品，TCE未来可能成为下一代广谱免疫用药，未来基石用药是PD1双抗+ADC+TCE的黄金三角；而这三者中，单靶点ADC时代中国已经世界一流、双靶点ADC中国全面领先，PD1双抗产品几乎都来自中国，TCE中美目前并驾齐驱。大药企疯狂并购中国产品本质是在布局下一个时代基石用药的卡位生态；　　PD1全球领域销售500亿美金，在未来销售预期800亿美金市场，考虑双抗比PD1疗效更好，患者生存获益延长，对应未来双抗市场规模可能超过1000亿，这部分市场可能全部由来自中国产品占有；如果考虑12%的销售分成和PE给合适估值，目前市场各家的双抗估值并没有泡沫；其次PD1/VEGF双抗仅解决PD1中高表达人群，而PD1低表达（人群占比50%）和PD1耐药市场这一广阔蓝海并没有有效药物，PD1/IL产品可能对这个领域有一定突破，未来也是可能接近千亿的蓝海市场值得开发；　　3-5月ASCO数据的阶段已经兑现，接下来是炒BD阶段，预计下半年WCLC和ESMO会议还会有企业的数据出来，带来BD的确定性，所以Q3是比较适合BD类型标的的投资；　　Q3-Q4开始困境反转类公司的基本面可能有所体现，是下阶段我们需要挖掘的一些领域；AI医疗随着可能的海外应用和多模态可能提升也可能有阶段性交易机会；　　整体来讲，后续依然是创新药BD兑现阶段，而之后在接近四季度可能会有一些低位板块的阶段性表现，如果创新药有所回调可能是布局明年的一次机会；中国的医药产业经历了转型阵痛，终于在24-25年之际迎来了开花结果的产业收获期，这是一次系统性能力提升，弥足珍贵，希望与投资人共享未来数年的中国科技创新发展红利","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:06:09.773Z","mo":"国内经济处于低通胀时代，消费部分疲弱，地产依然还在磨底阶段，房地产不再成为居民财富效应工具，居民储蓄率高居不下，新环境下需要新财富工具来稳定预期提高居民获得感，权益类资产目前有可能接棒这一角色；中国工程师红利带来的科技产业崛起给这一轮整体预期偏弱的环境一剂强心针，高分红高股息资产稳定了市场，成长性板块不断进攻向上形成了整体缓慢牛市的阶段性格局。　　就未来来看，我们依然看好证券市场的持续活跃。在具体行业上，能够有全球竞争力可以出海拿到超额收益的科技产业会是长期主旋律，这里包括创新药、海外AI算力产业、AI应用等。整体来讲这些行业的景气度依然没有走完，会是全年主线。机器人、固态电池有望持续有结构性机会，这两类0-1产业，产业拐点临近有望在明年带动主线行情。","fund":{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"db20909245","stockType":"fund_manager","exchange":"fm","tickerId":192425235320,"name":"桑翔宇"}]},"announcement":{"linkText":"华安医药生物股票型发起式证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1349253","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3d17fea5b3eb0541c2f","date":"2025-03-30T16:00:00.000Z","stockId":3000000022690,"sao":"一季度随着DeepSeek打破美国例外论叙事、民营经济座谈会暖风频吹，市场整体风险偏好较高，市场相对活跃；医药行业陆续有政策出台，集采纠偏（打破市场对于医药收缩性政策的悲观看法）、全产业链支持创新药政策陆续出台，对于整个医药板块情绪修复极大；一季度创新药板块表现较好；随着AI大模型的逐步成熟，AI应用元年到来，医疗AI作为垂类最具备潜力的方向备受关注，在一季度也有阶段性表现。　　进入二季度，市场逐步从“预期市场”走入看重兑现的“基本面市场”、美国对等关税影响带来了极大的市场波动和不确定性，考虑到中美博弈的长期性，下一阶段的配置思路是在不确定性中寻找确定性的结构性机会。　　（一）创新药板块迎来三端共振、类比此前中国新能源汽车板块的崛起　　全球抢购中国创新药优质资产：全球5000万美金以上的BD交易中，来自中国的比例从2020年不到5%，迅速提升到2024年的30%以上，2025年一季度交易比例进一步提升，全球在抢购中国优质创新药资产；背后的原因其实很简单，性价比是硬道理，中国医药产业链在早期临床研发推进的速度和成本明显低于欧美，同时中国工程师红利优势带来了已知靶点的大分子工程优化能力，综合成本是美国的1/3-1/5；在大分子时代，诸如ADC、双抗、TCE等领域中国已经实现弯道超车；　　创新药的三端共振：政策端医保局给予了创新药最大的支持、供给端创新药产品高质量高性价比、报表端biotech龙头公司逐步迎来盈利潮　　今年节奏好于去年、是基本面的强兑现年份：去年创新药在ASCO会议时期，大品种不多，数据差强人意；但是今年创新药很大的不同在于，龙头企业大品种很多、数据普遍优秀；　　中国医药产业供给端随着近几年的逐步优化升级，已经成为新质生产力重要一环，产业景气周期加速向上，属于医药确定性最强板块。　　（二）内需复苏困境反转、国产自主可控带来避险的确定性　　24年医药行业因为反腐、疫情退坡等诸多因素，行业基本面从报表端环比向下；但目前看价格战见底、多数行业看到了积极复苏的前置信号，今年二季度开始很多板块基本面开始弱复苏；　　中美博弈背景下，诸如器械、耗材、血制品等过程替代空间大的行业可能迎来配置契机　　（三）AI医疗有望改变国内医疗生态、目前属于萌芽早期　　国内医疗资源区域分配不均、科室能力参差不齐，分级诊疗推进节奏较慢，本质还是优质的医疗供给有瓶颈；目前国内科技公司如百川智能等在医疗AI上做了深度尝试，推出了AI儿科医生等B端垂类产品，有望解决基层诊疗能力不足，等级医院供给能力难以提升的问题，对中国医疗产业可能有深远影响；　　国内目前AI医疗还存在卡点：一方面，国内目前最优质的医疗数据尚在孤岛状态，需要进一步市场化交易打通；另一方面，国内目前AI辅助诊断还无法单独收费，产品目前提供给C端用户的体验也有待升级；　　目前AI医疗可能是全年的主题，今年催化剂多，是不容忽视的配置线，需要等到进一步的多模态能力提升、风险偏好提升带来板块贝塔；整体看AI医疗目前还属于类似20年之前创新药的产业萌芽阶段，但是未来产业上限极高，值得期待；　　面对中美不确定性，我们需要保持乐观的态度，每一次危机和动荡都是机遇；不尽狂澜走沧海、一拳天与压潮头，产业和时代的趋势浩浩荡荡，我们何其幸运能够参与到历史事件中来，守得云开见月明，前方海阔天空。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T14:06:09.770Z","fund":{"_id":3000000022690,"__csrcFundId":14558,"stockCode":"022690","masterFundShortName":"华安医药生物股票发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":22690,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安医药生物股票发起式(022690)","lastUpdated":"2026-05-01T03:36:41.238Z","name":"华安医药生物股票型发起式证券投资基金","pinyin":"hayyswgpxfqszqtzjj","fundCollectionId":4000050040000,"setUpAssetScale":14297983.32,"setUpDate":"2024-12-24T16:00:00.000Z","setUpShares":14297983.32,"inceptionDate":"2024-12-26T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"db20909245","stockType":"fund_manager","exchange":"fm","tickerId":192425235320,"name":"桑翔宇"}]},"announcement":{"linkText":"华安医药生物股票型发起式证券投资基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1273003","linkType":"PDF","source":"csrc_pdf"}}]}